Trevi Therapeutics, Inc. (TRVI): Price and Financial Metrics


Trevi Therapeutics, Inc. (TRVI): $1.91

0.03 (+1.60%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

TRVI Stock Price Chart Interactive Chart >

Price chart for TRVI

TRVI Price/Volume Stats

Current price $1.91 52-week high $4.68
Prev. close $1.88 52-week low $0.46
Day low $1.88 Volume 48,700
Day high $1.96 Avg. volume 817,914
50-day MA $1.89 Dividend yield N/A
200-day MA $2.44 Market Cap 114.45M

Trevi Therapeutics, Inc. (TRVI) Company Bio


Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT.


TRVI Latest News Stream


Event/Time News Detail
Loading, please wait...

TRVI Latest Social Stream


Loading social stream, please wait...

View Full TRVI Social Stream

Latest TRVI News From Around the Web

Below are the latest news stories about TREVI THERAPEUTICS INC that investors may wish to consider to help them evaluate TRVI as an investment opportunity.

Trevi Therapeutics Appoints Pharma Industry Veteran as Chief Medical Officer

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced the appointment of David Clark, MD, MRCP, as Chief Medical Officer (CMO). Dr. Clark will join Trevi's executive team and be responsible for the strategy and executi

Yahoo | November 14, 2022

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Trevi Therapeutics (TRVI) and Sight Sciences (SGHT)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Trevi Therapeutics (TRVI – Research Report) and Sight Sciences (SGHT – Research Report). Trevi Therapeutics (TRVI) In a report released today, Serge Belanger from Needham maintained a Buy rating on Trevi Therapeutics, with a price target of $8.00. The company's shares closed last Thursday at $1.93. According to TipRanks.

Catie Powers on TipRanks | November 11, 2022

Trevi Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced financial results for the quarter ended September 30, 2022, as well as provided business updates.

Yahoo | November 10, 2022

Trevi Therapeutics to Participate at the Stifel 2022 Healthcare Conference

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of serious chronic cough conditions, today announced that Jennifer Good, President and Chief Executive Officer, and Lisa Delfini, Chief Financial Officer, will participate in a fireside chat at the Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022, at 3:35 p.m. ET.

Yahoo | November 8, 2022

Trevi Therapeutics to Report Q3 2022 Financial Results and Provide a Corporate Update on November 10, 2022

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of serious chronic cough conditions, today announced that management will host a conference call and live audio webcast on Thursday, November 10, 2022, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the third quarter ended September 30, 2022.

Yahoo | November 3, 2022

Read More 'TRVI' Stories Here

TRVI Price Returns

1-mo -3.05%
3-mo -40.50%
6-mo -23.90%
1-year 101.05%
3-year -44.15%
5-year N/A
YTD 144.18%
2021 -67.68%
2020 -35.47%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6122 seconds.